Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study.
This study analyzed the change in breast density in women receiving tamoxifen treatment using 3-D MRI. Sixteen women were studied. Each woman received breast MRI before and after tamoxifen. The breast and the fibroglandular tissue were segmented using a computer-assisted algorithm, based on T1-weighted images. The fibroglandular tissue volume (FV) and breast volume (BV) were measured and the ratio was calculated as the percent breast density (%BD). The changes in breast volume (ΔBV), fibroglandular tissue volume (ΔFV) and percent density (Δ%BD) between two MRI studies were analyzed and correlated with treatment duration and baseline breast density. The ΔFV showed a reduction in all 16 women. The Δ%BD showed a mean reduction of 5.8%. The reduction of FV was significantly correlated with baseline FV (P<.001) and treatment duration (P=.03). The percentage change in FV was correlated with duration (P=.049). The reduction in %BD was positively correlated with baseline %BD (P=.02). Women with higher baseline %BD showed more reduction of %BD. Three-dimensional MRI may be useful for the measurement of the small changes of ΔFV and Δ%BD after tamoxifen. These changes can potentially be used to correlate with the future reduction of cancer risk.
Chen
Jeon-Hor
JH
Tu & Yuen Center for Functional Onco-Imaging and Department of Radiological Science, University of California Irvine, Irvine, CA 92697, USA.
Chang
Yeun-Chung
YC
Chang
Daniel
D
Wang
Yi-Ting
YT
Nie
Ke
K
Chang
Ruey-Feng
RF
Nalcioglu
Orhan
O
Huang
Chiun-Sheng
CS
Su
Min-Ying
MY
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001940:Breast / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen